TAGRISSO (OSIMERTINIB) SHOWS CLINICAL ACTIVITY IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM LUNG CANCER
Osimertinib data reported at ASCO 2016 demonstrated improved neurological function in patients with EGFRm NSCLC and leptomeningeal disease Latest results reinforce pre-clinical evidence that osimertinib crosses the blood-brain barrier